Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
- Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
- Cancer Center of Kansas - Wichita
Wichita, Kansas, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Vanderbilt University/ingram Cancer Center
Nashville, Tennessee, United States
- M D Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Oct 2019
- Primary completion
- 23 Aug 2021
- Completion
- 2 Jul 2024
- Last update posted
- 22 Aug 2024
- Registered enrollment
- 102
- Registry id
- NCT03981614
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.